Allergy Therapeutics (AGY.L) Stock Price
£8.3 3.8%
to add to portfolio
AI Score
-
Alternative
4 -
Fundamental
1 -
Technical
5
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Allergy Therapeutics, AI stock picks, stock alerts and much more.
AGY.L AI Stock Analysis
AI stock analysis for AGY.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Allergy Therapeutics (AGY.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Allergy Therapeutics (AGY.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Allergy Therapeutics (AGY.L), currently trading at £8.3, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About AGY.L
-
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments.
-
Symbol
AGY.L
-
Market
LSE
-
Industry
Drug Manufacturers - Specialty & Generic
-
Market Cap
395.6M
Similar Stocks
 |
Shield Therapeutics STX.L |
£8.2 6.5% |
5 |
 |
Haleon plc HLN.L |
£364.1 0.3% |
7 |
 |
HUTCHMED (China) Limited HCM.L |
£239 2.6% |
6 |
 |
Hikma Pharmaceuticals PLC HIK.L |
£1660 0.2% |
6 |
 |
ECO Animal Health Group EAH.L |
£73.5 0.00% |
7 |
News
AGY.L Alternative Data
Web Traffic
Allergy Therapeutics receives an estimated 1078 monthly visitors to allergytherapeutics.com, which is down by -57.6% over the last month.
-
Web Traffic
1078
-
Change from Previous Month
57.6%
-
3 Month Change
6.8%
-
YoY Change
6.8%
Instagram Followers
Allergy Therapeutics has 63 Instagram Followers on its main Instagram account, down by -1.6% over the last month.
-
Instagram Followers
63
-
Daily Change
0%
-
1 Month Change
1.6%
-
3 Month Change
1.6%
-
YoY Change
1.6%
Youtube Subscribers
Allergy Therapeutics has 27 subscribers on its main Youtube channel.
-
Youtube Subscribers
27
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Reddit Mentions
Allergy Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
11,406 are following Allergy Therapeutics on LinkedIn, up by 1.1% over the last month.
-
LinkedIn Followers
11406
-
Daily Change
1.1%
-
1 Month Change
1.1%
-
3 Month Change
3.9%
-
YoY Change
3.9%
Business Outlook
According to employee reviews, the business outlook among employees at Allergy Therapeutics is 27 out of 100 (bearish).
-
Business Outlook
27
-
Change from Previous Month
0%
-
3 Month Change
58.8%
-
YoY Change
58.8%
LinkedIn Employees
According to LinkedIn, Allergy Therapeutics has 366 employees.
-
LinkedIn Employees
366
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.8%
-
YoY Change
0.8%
News Mentions
Allergy Therapeutics was mentioned 3 times in the news yesterday.
-
News Mentions
3
-
Daily Change
200%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
AGY.L Financials
AGY.L Key Metrics
-
Total Revenue
£34M
-
Net Income
-£11.1M
-
Earnings per Share
-£0.0023
-
Free cash flow
-£9.2M
-
EBITDA
-£6.5M
-
EBITDA Ratio
-0.18995
-
Total Assets
£73M
AGY.L 2-year Revenue & Income
AGY.L 2-year Free Cash Flow
AGY.L Technicals
AGY.L SMA
AGY.L RSI
FAQ
What's the current price of Allergy Therapeutics (AGY.L) Stock?
The price of an Allergy Therapeutics (AGY.L) share is £8.3.
What's the market cap of Allergy Therapeutics?
The current market cap of Allergy Therapeutics is 395.6M.
Should I buy or sell AGY.L?
Allergy Therapeutics exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.
Is Allergy Therapeutics a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Allergy Therapeutics stock. There are several bearish signals and market challenges that could negatively impact Allergy Therapeutics' future performance, suggesting that caution should be exercised before making any investment decisions.
Is now a good time to buy Allergy Therapeutics (AGY.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Allergy Therapeutics stock right now, as the outlook appears bearish.
What are some stocks similar to Allergy Therapeutics (AGY.L) that investors often compare it to?
Allergy Therapeutics (AGY.L) is often compared to similar stocks such as Shield Therapeutics, Haleon plc, HUTCHMED (China) Limited, Hikma Pharmaceuticals PLC and ECO Animal Health Group.
What is the forecast for Allergy Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Allergy Therapeutics' stock price to be around £7.77 in 2026. Starting from the current price of £8.3, this represents a 6.4% change in price, indicating a bearish outlook for the stock.
How to buy Allergy Therapeutics (AGY.L) Stock?
Allergy Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Allergy Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.